|Bid||77.66 x 1200|
|Ask||86.10 x 800|
|Day's Range||80.23 - 81.93|
|52 Week Range||56.91 - 85.91|
|Beta (3Y Monthly)||0.72|
|PE Ratio (TTM)||74.37|
|Earnings Date||Jul 30, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||0.80 (1.00%)|
|1y Target Est||89.40|
QIAGEN's (QGEN) Sample to Insight workflows and expertise in developing diagnostic solutions will aptly compliment Inovio regarding Precision Medicine in immuno-oncology.
The latest acquisition aligns with Thermo Fisher's (TMO) strategy of enhancing capabilities of its Pharma Services through the right balance of capital investment, and merger and acquisition.
Benefiting from new products and an improved sales force performance, Integra LifeSciences (IART) projects speedy organic growth in the second half of 2019.
According to Medtronic (MDT), interbody implants material and shape play a vital role in the bone growth process during fusions and presently, titanium interbody devices are rapidly becoming popular.
Abbott (ABT) is attracting constant attention with developments in its flagship, sensor-based continuous glucose monitoring (CGM) system called FreeStyle Libre System.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
National Vision's (EYE) consistent strength in comps is owing to higher customer transaction for the past 69 straight quarters.
Syneos Health (SYNH) sees strong year-over-year revenue growth across both operating segments ??? Clinical Solutions and Commercial Solutions.
Cardinal Health (CAH) Q3 results benefit from strong performance by Pharmaceutical segment and higher revenues. However, sluggishness in the Medical segment remains a concern.
Bio-Rad (BIO) witnesses revenue growth at the Life Sciences segment in Q1 on strength in cell biology, droplet Digital PCR and other product lines.
Wright Medical (WMGI) Q1 results benefit from higher revenues, solid show by Lower as well as Upper Extremities segments and gross margin expansion. However, rising costs remain a woe.
Bruker's (BRKR) current focus on product development through higher R&D investment stokes investors' positive sentiment around the stock.